

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/848,735	05/19/2004		Kevin T. Schomacker	MDS-033C1	7328
51414	7590	09/11/2006		EXAMINER	
GOODWI			SUNG, CHRISTINE		
PATENT A			ART UNIT	PAPER NUMBER	
BOSTON, 1	MA 0210	09-2881	2884		
				DATE MAILED: 09/11/2000	5

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
	10/848,735	SCHOMACKER ET AL.					
Office Action Summary	Examiner	Art Unit					
	Christine Sung	2884					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be timwill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	Lely filed the mailing date of this communication. D (35 U.S.C. § 133).					
Status							
1) Responsive to communication(s) filed on 22 Ju	<u>une 2006</u> .						
2a) This action is FINAL . 2b) This	action is non-final.	•					
•	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims							
4) ⊠ Claim(s) 47-82 is/are pending in the applicatio 4a) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 47-82 is/are rejected. 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or	wn from consideration.						
Application Papers							
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	epted or b) objected to by the I drawing(s) be held in abeyance. See tion is required if the drawing(s) is objected.	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).					
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. Certified copies of the priority documents have been received in Application No Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s) 1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	(PTO-413)					
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date <u>0606</u>. 	Paper No(s)/Mail D						

Application/Control Number: 10/848,735 Page 2

Art Unit: 2884

Response to Amendment

1. The amendment filed on June 22, 2006 has been accepted.

Double Patenting

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

- 3. Claims 47-50, 56-69, 72, 75, 78 and 81 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 1, 2, 3, 1, 21, 22, 23, 24, 25, 26, 27, 2, 3, 4, 5, 38, 38, 39, 1, 1, 38 and 38, respectively, of U.S. Patent No. 6,818,903 B2. Although the conflicting claims are not identical, they are not patentably distinct from each other because they both disclose determining a condition of a tissue sample.
- 4. Claims 51-55 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-3 of U.S. Patent No. 6,818,903B2 in view of Fulghum (US Pre Grant Publication 2003/0232445 A1).

Application/Control Number: 10/848,735 Page 3

Art Unit: 2884

Regarding claims 51-55, US Patent 6,818,903 B2 does not explicitly claim determining the health of the tissue, or whether the tissue is cancerous or the specific tissue type. However, all of the claimed types of tissue identification are known.

Regarding claims 51 and 52, Fulghum discloses determining whether the tissue is cancerous (paragraphs [0016] and [0063]).

Regarding claim 53, Fulghum discloses that the tissue is gastro-esophageal tissue (paragraph [0016]).

Regarding claims 54-55, Fulghum discloses that the tissue sample comprises epithelial cells (claim 52).

5. Claims 71, 73-74, 76, 77, 79-80 and 82 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1 and 38 of U.S. Patent No. 6,818,903 B2 in view of Lemelson (US Patent 5,735,276 A).

Regarding the claims, US Patent No. 6,818,903 B2 discloses the limitations set forth in the respective independent claims but does not specify the relationship between the first and second collection angles.

Regarding the claims, Lemelson discloses an apparatus for scanning an evaluating tissue where the first and second angles are substantially equal and opposite relative to the collection axis (see figure 4).

Response to Arguments

6. Applicant's arguments filed on June 22, 2006 have been fully considered but they are not persuasive.

Application/Control Number: 10/848,735 Page 4

Art Unit: 2884

7. Applicant argues that the Fulghum reference does not qualify as a 102(e) reference. The instant application has an effective priority date of July 9, 2002. The Fulghum reference has an effective filing date of January 18, 2002 and therefore qualifies as prior art under 35 U.S.C. 102 (e). See MPEP section 706.02(a).

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christine Sung whose telephone number is 571-272-2448. The examiner can normally be reached on Monday- Friday 7-3 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Porta can be reached on 571-272-2444. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Christine Sung Examiner Art Unit 2884

PRIMARY EXAMINER